Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced or Metastatic Solid TumorLiver Failure
Interventions
DRUG

Sacituzumab Govitecan-hziy

Administered intravenously

Trial Locations (10)

19713

RECRUITING

Christiana Care Health Services, Newark

21201

RECRUITING

University of Maryland, Baltimore

33000

RECRUITING

Institut Bergonie Medical Oncology, Bordeaux

69373

RECRUITING

Centre Leon Berard, Lyon

77030

RECRUITING

Oncology Consultants, P.A., Houston

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston

78215

RECRUITING

Texas Liver Institute, San Antonio

78229

RECRUITING

NEXT Oncology, San Antonio

78758

WITHDRAWN

NEXT Austin, Austin

90813

SUSPENDED

Pacific Shores Medical Group, Long Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY